In many respects, gamification represents what many analysts today consider to be the final frontier in marketing. The most prominent incarnations able to captivate consumers and maximize brand or product engagement metrics by interacting with end users in a way that both entertains and rewards them. This is especially true when it comes to connecting with newer generations that have been raised in an environment where gaming was ubiquitous, with games available and being played everywhere from consoles and computers, to smartphones and tablets. The implications for the deployment of gamification in marketing and social media when it comes to capturing this much sought after demographic are extremely compelling, and the technique has already become a major focus for some of the world’s top brands.

One of the keys to the importance of gamification as it relates to audience engagement for any business is how big data can be used to generate a wealth of insights into the behavior of individual customers. Harnessing the immense depth of information via powerful algorithms and automated predictive analysis is no easy task, however, and it requires talented engineers to both understand how best to setup a system for data capture, and actually decode the resulting datasets so that actionable intelligence can be utilized for tailored marketing.

According to a recent report compiled by digital tech and telecom focused research and strategic analysis firm Mind Commerce, the gamification market is on track to top $10 billion within the next five years alone. Echoing analysis by the Association for Continuing Legal Education projects a $1.7 billion market this year that is set to more than triple by 2018. By just looking at how eLearning game design focused firm Ambient Insight valued 2012 global revenue in the learning games market alone at around $3.9 billion, with a five year CAGR of 18 percent, one can begin to understand just how big the gamification space has already become, and where it is going.

Any way you slice it, gamification is rapidly transforming everything from education to marketing, and the companies which can provide toolsets and platforms to enable its proliferation are poised to make a mint. One such company is Moxian (OTCQB: MOXC), whose gamification and analytics offerings are enmeshed within a truly 21st century social networking driven platform which lets the company’s merchant clients run targeted advertising campaigns and promotions, while also fostering increasingly tight-knit end user relationships. The Moxian platform marries together social networking with the company’s proprietary virtual currencies MO-Coin and MO-Points, allowing end users to play highly enjoyable games and earn currency in the process which can then be redeemed for prizes that are sponsored by Moxian and its client merchants.

With a platform that seamlessly integrates social networking community and a component designed entirely for merchants and businesses, which is backed up by a gamified reward/loyalty system that keeps customers coming back for more, Moxian is able to deliver to merchants a multi-channel social marketing ecosystem approach that allows them to leverage social media in order to grow their business. Moxian is focused squarely on the SME market, which is hungry for such robust online tools as the kind of intelligent data capture, learning and analytics provided by MOXC’s proprietary social customer relationship management (SCRM) engine. The kinds of tools that help drive customer engagement as well as retention, and provide businesses with the kind of comprehensive advertising capabilities and marketing access they need to really push messages out to their consumer base(s).

The Moxian+ platform, originally developed in Shenzhen, China, is executed on the client side via customized apps that are designed for both end users and for businesses. This dual pronged approach allows MOXC to efficiently address both ends of the spectrum through parallel development, rolling out new features via each app. With over 650 million internet users in China alone, MOXC’s established presence grants the company impressive bedrock access to a rich SME landscape that is fueled by a burgeoning Chinese ecommerce market which is set to hit upwards of $1 trillion by 2018. Ecommerce in China is being driven inexorably forward by juggernauts like Alibaba (NYSE: BABA), an increasingly globally-focused operator, and with no upper limit in sight, MOXC’s developers truly have their work cut out for them.

Needless to say, the global traction potential for the Moxian+ platform is substantial and investors should take note that the Chinese ecommerce space alone is set to expand from 10 percent of retail as of late last year, to over 15 percent of all retail sales by as early as 2017.

For more information, visit the company’s website at http://ir.moxian.com/html-en/

Let us hear your thoughts: Moxian, Inc. Message Board

Earlier today, Stellar Biotechnologies, Inc. (NASDAQ: SBOT) (TSX-V: KLH) announced the presentation of a preclinical poster relating to its ongoing research on Clostridium difficile. The poster, which was presented at the Society for Glycobiology 2015 Annual Meeting in San Francisco, California, reported data from the company’s studies into the potential development of C. difficile cell surface polysaccharide-KLH conjugate vaccines, or active immunotherapies, for the treatment of C. difficile infection.

Although C. difficile bacteria is normally present in the intestine, it sometimes overgrows as a result of antibiotic use. The infection that stems from this overgrowth has been linked to a host of dangerous side effects – including severe diarrhea and life-threatening intestinal conditions, such as colitis. Currently, the rate of U.S. cases of C. difficile overgrowth is at an all-time high. According to a 2011 study by the Centers for Disease Control and Prevention, C. difficile accounts for roughly 500,000 infections in the U.S. each year, costing patients and insurers approximately $4.8 billion in related medical expenses. Among those patients, an estimated 29,000 die within 30 days following initial diagnosis, further highlighting the importance of Stellar’s research program.

Stellar is the global leader in the sustainable manufacture of keyhole limpet hemocyanin (KLH) protein, which is an important immune-stimulating molecule widely used as an active pharmaceutical ingredient in immunotherapies. As a result of its proprietary method of sustainably producing GMP grade KLH, the company has partnered with a host of multinational pharmaceutical firms, renowned research centers and developers of active immunotherapies and therapeutic vaccines to address critically underserved indications in the biopharmaceutical industry.

Last month, the company successfully leveraged the marketability of its KLH protein by uplisting to the NASDAQ Capital Market. Following this move, Stellar reiterated intentions to expand its manufacturing capacity in order to better address the growing demand for KLH protein in immunotherapy. For prospective shareholders, the company’s recent progress represents an important step toward achieving sustainable corporate growth in the months to come.

To view the poster, Clostridium difficile Surface Polysaccharide-KLH Conjugate Vaccine Induced Th17-Featured Adaptive Immune Responses in Mice, visit http://content.equisolve.net/stellarbiotechnologies/media/0e37609debe1b998c4ccef5dd2a84a82.pdf

For more information, visit www.stellarbiotech.com

The growing cannabis industry in the United States has sparked both controversy and interest in its financial impact. Freedom Leaf, Inc. owns and operates the Freedom Leaf Magazine, which is designed to inform readers about industry, entertainment, and technological news centered on the cannabis business. This multi-media news outlet taps into the emerging industry’s latest information, legislation, and trending topics. The magazine is a staple for medical and recreational dispensaries, smoke and vape shops, and other organizations. Freedom Leaf actively promotes and supports the legalization of medical and recreational marijuana through its magazine, which is set to eclipse the milestone of one million copies in circulation in 2016.

The company recently announced mounting interest from overseas prospects who want in on this evolving industry. These companies are seeking access to the Freedom Leaf brand, which will allow them to market, sell, advertise, offer services, and create events under its name. Freedom Leaf is currently negotiating to license its brand in four European countries.

Cliff Perry, CEO of Freedom Leaf, Inc. stated, “We’re a magnet to attract mergers and acquisitions, incubation of new companies and spinoffs.” He added, “Our news, media and entertainment platforms and other properties raise awareness for investors and seed more potential deals.”

“The negotiations are very positive,” Perry said. “We’re in discussions with two different companies in what promises to be a meaningful endeavor to speed our growth.”

Freedom Leaf Inc. has tremendously expanded its name since its creation two years ago. By solidifying its impact and service to the cannabis industry, the company and its magazine will continue to advocate legalizing marijuana while providing newsworthy articles about the industry to readers. These overseas contracts will increase Freedom Leaf’s revenue and overseas presence.

For more information, visit http://freedomleaf.com

Let us hear your thoughts: Freedom Leaf Inc. Message Board

Given the latest official data on prostate cancer prevalence compiled by the CDC and the GLOBOCAN project, over 1.1 million cases of what is the fourth most common cancer in both sexes combined and the second most common cancer in men, were reported back in 2012 alone. Prostate cancer accounts for roughly 15 percent of all cancers in men and is the fifth most lethal, with around 307,000 deaths in 2012. A continually rising rate of incidents are being reported in developed economies as prostate specific antigen (PSA) tests become more and more ubiquitous, giving investors a clear portrait of the demand landscape moving forward for therapeutics. Incident rates for prostate cancer will only rise in parallel (or greater) alongside overall cancer rates, for which the CDC estimates the figure will rise by 36.8 percent to 19.3 million new cases by 2025.

PSA tests have helped to rapidly differentiate prostate cancer from a common condition where the prostate enlarges on its own, which is almost inevitable in men as they age, known as benign prostatic hyperplasia (BPH). However, even with the emergence of five new drugs since 2010 from players like Dendreon (OTC: DNDNQ) and Medivation (NASDAQ: MDVN) working in partnership with Astellas (OTC: ALPMY), as well as heavy-hitters such as Sanofi (NYSE: SNY), Johnson & Johnson (NYSE: JNJ) and Bayer (OTC: BAYRY) – the space is still largely underserved, with extant indications only achieving marginal efficacy. Even the more ingenious indications, which utilize aspects of personalized medicine to program a specific patient’s immune system, have seen only partial completeness in achieving the desired endpoints.

If patients can be diagnosed early enough, localized prostate cancer is more easily treatable, but there is currently no curative option available for patients once the disease has progressed to the point of being classed as castration-resistant prostate cancer (CRPC). According to forecasts by energy and healthcare research group GlobalData, the number of late-stage pipeline agents that are commercially available will nearly double by 2023, with the vast majority aimed at CRPC, triggering a three-fold increase in the size of the therapy market across the nine major global economies. We are looking at a 12.4 percent CAGR from 2013 through 2023 according to GlobalData, when the therapeutics market will hit upwards of $8.3 billion, driven by the advent of new premium-priced therapies and label extensions of extant commercial indications. The robust pipeline for new therapies is particularly interesting as many of the developing candidates possess wholly unique mechanisms of action which set them apart from existing treatments, as well as the targeting of different proteins and pathways.

One of the most exciting developers in this game today is a clinical stage biopharma with truly innovative proprietary vaccine technology at their disposal, OncBioMune Pharmaceuticals (OTCQB: OBMP), which recently secured Notices of Allowance for patents on its leading prostate cancer vaccine candidate ProscaVax™ in both China and Ukraine. Already well-established via a phase 1/2 clinical trial in biopsy confirmed patients with elevated PSA, ProscaVax, which is designed to stimulate the host immune system into attacking the cancer without harming the patient, was administered in the phase 1/2 trail using a one-two punch protocol developed from insights and techniques employed in breast cancer vaccinations. Several weeks after an initial round containing a pre-tuned concentration of prostate specific antigen and biological adjuvant, serum PSA concentrations are again evaluated before a second course of shots are administered in combination with low dose IL-2 (a cytokine signaling molecule, interleukin 2) over a period of about six months.

The Chinese and Ukrainian Notices of Allowance add substantially to OBMP’s already solid IP position and protect the vaccine in those countries through 2031, reinforcing the earlier USPTO patent for ProscaVax, as well as the related Notice of Allowance for an additional patent application that was filed with the USPTO. Currently nearing completion of a fully funded phase 1 trial this month (in part paid for by the US Navy Cancer Vaccine Program) that is being conducted at UCSD Medical School under an IND from the FDA, ProscaVax is already slated to begin its key phase 2 clinical study early next year at Harvard Cancer Centers, and could rapidly become a leading therapeutic vaccine with serious profitability for OncBioMune once FDA approval has been granted.

Phase 1 trial data was recently offered in a poster presentation at the CRI-CIMT-EATI-AACR: Inaugural International Cancer Immunotherapy Conference in New York and the results offered in this poster presentation roundly supports the work OBMP has been doing, showing increased immunity to the PSA antigen after administration of the vaccine, as well as a delimiting of the PSA progression rate in those who had previously received standard therapies. With eight out of nine patients in the phase 1 trial showing increased immune response to PSA at (validated via lymphocyte blastogenesis assay) 31 weeks after the first vaccine and there being an unmistakably clear lack of toxicity as a result of ProscaVax being administered, OBMP is now well-equipped to receive FDA clearance for phase 2.

The company’s secondary candidate, OvcaVax, has similar potential in the $55.5 million global breast cancer therapeutics market, which is expected to hit upwards of $7.8 billion by 2023, growing at a CAGR of around 58.3 percent according to a recent report published by Transparency Market Research. OncBioMune actually has a much larger and equally compelling portfolio of targeted therapies under its belt as well, some of which are biosimilars to current blockbuster drugs. OvcaVax could put OBMP in direct competition with breast cancer therapeutic majors like Roche’s (OTC: RHHBY) Genentech, as well as Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), Novartis (NYSE: NVS), and AstraZeneca (NYSE: AZN).

In fact, OncBioMune actually obtained the first U.S. patent on a breast cancer vaccine back in 1994 and was also the first to employ GM-CSF and IL-2 cytokines as adjuvants. The company is currently heavily focused on tumor escape mechanisms in breast cancer via ongoing study of tumor stroma and the microenvironment, setting the company up for potential breakthroughs in specific adaptive immunotherapies, and OBMP already has some promising preliminary results in this area to boast of. The company’s recent ticker change and up-listing to OTCQB following the acquisition of Quint Media and approval by FINRA, as well as the tapping of former president and CEO of Entergy (NYSE: ETR) subsidiary Entergy New Orleans, Charles L. Rice, Jr. to its Board of Directors, shows just how serious a contender the company has now become. From both a clinical development and business model fundamentals standpoint OBMP (currently trading at $2.50 per share) is now starting to turn heads in the investment community as one of the most promising up-and-comer clinical-stage biopharmas available.

OncBioMune has an extremely promising immuno-oncology vaccine candidate in ProscaVax that is ready for phase 2 and which can directly address the unmet demand for a powerful prostate cancer therapeutic. The company has taken the proper steps to massively increase its market exposure and the commercial potential for OBMP’s broader pipeline is just starting to be understood by investors. OncBioMune has certainly become one to watch and interested parties should keep their ears to the ground for news about the upcoming phase 2 work on ProscaVax.

Take a closer look, visit http://oncbiomune.com/

Hemp, Inc. recently announced the execution of a definitive five year term agreement to sell its industrial hemp fiber to Hemp Blue, a premium denim apparel brand. Through this partnership, Hemp Blue is seeking to become the first brand to produce apparel made from American-grown hemp since Levi Strauss did so decades ago. In recent weeks, Hemp Blue has taken to Kickstarter to spread the word about its eco-friendly mission while offering supporters an opportunity to become among the first people to claim items from their initial collection of hemp-based clothing. With just two days left in the campaign, Hemp Blue has surpassed its funding goal, demonstrating the marketability of its innovative business model.

“I’m amazed at how well Hemp Blue is doing,” Bruce Perlowin, chief executive officer of Hemp, Inc. stated in a news release. “Only 33 percent of the Kickstarter campaigns in the fashion division ever get completed or are successful. Their performance is quite impressive.”

To date, more than 300 individual backers have contributed to Hemp Blue’s campaign, which it has stressed is “a movement toward a more sustainable future.” In addition to spreading the message about the benefits of hemp for both people and the planet, Hemp Blue is also supporting the ongoing movement to legalize industrial hemp by pledging to donate a portion of their profits to organizations that fight for the cause.

As Hemp Blue inches toward its initial goal, Hemp, Inc. is continuing to push forward in the industrial hemp industry. Through wholly-owned subsidiary Industrial Hemp Manufacturing, LLC, the company is rapidly approaching the completion of its decortication facility in Spring Hope, North Carolina. Initially, the facility will be used to process kenaf, which is already located on site in North Carolina. According to David Schmitt, chief operating officer of Industrial Hemp Manufacturing, the company is currently awaiting the first frost, which will play a key role in killing and defoliating the crop before it is ready to bale.

For both Hemp, Inc. and Hemp Blue, the coming months represent an exciting opportunity to promote strong growth. Look for Hemp, Inc. to benefit from its agreement with Hemp Blue moving forward, providing a foothold in the emerging apparel industry that’s stemming from the ongoing push for the nationwide legalization of industrial hemp production.

For more information, visit www.hempinc.com

Let us hear your thoughts: Hemp, Inc. Message Board

In November, Star Mountain Resources, Inc. completed the acquisition of Balmat Holding Corporation – including St. Lawrence Zinc Company, LLC and its mining operations in the Balmat mining district of New York – after meeting all of the closing conditions of purchase agreements with both Northern Zinc, LLC and HudBay Minerals, Inc. Following the announcement, the company outlined plans to upgrade and modernize certain infrastructure systems and develop additional access to the newly-acquired mining areas in order to restart production in as little as six months.

Prospective shareholders were given an update on Star Mountain’s progress earlier this week when the Watertown Daily Times
published an article highlighting the company’s recent efforts to prepare to restart zinc production. Though the St. Lawrence Zinc Company mine has been shuttered since 2008, there are no legal or regulatory hurdles impeding the commencement of mining operations, leaving Star Mountain free to move forward on an accelerated schedule. Last week, representatives from the company met with St. Lawrence County officials to determine how local agencies can assist with the hiring process.

“It will be a two-step process, finding the workforce and training them,” Patrick J. Kelly, executive director of St. Lawrence County’s Industrial Development Agency, told reporters following the meetings. “We have agencies that have the expertise to help them identify a potential workforce.”

Initially, Star Mountain plans to hire about 50 employees, but the company expects to staff the Balmat mine with as many as 150 employees in the future. The schedule for additional hires will likely depend on the amount of time it takes to recommence active mining operations at the property. County legislator Joel L. LaPierre estimated that it would take roughly a year to begin extracting zinc from the mine in a recent interview.

The Balmat mining complex – including a 4,000-foot-deep mine, a 5,000-ton-per day flotation mill, an office building and necessary infrastructure for mine operation – was originally shuttered as a result of declining zinc prices, but forecasts for the coming months are promising. According to Mark Osterberg, president and chief operating officer of Star Mountain, zinc prices are set to increase beginning next year following the closure of several zinc mines with depleted reserves.

To read the Watertown Daily Times article, visit http://www.watertowndailytimes.com/news05/plans-to-reopen-st-lawrence-zinc-move-forward-20151130

For more information, visit www.starmountainresources.com

Let us hear your thoughts: Star Mountain Resources Inc. Message Board

Cherubim Interests, Inc. (OTC: CHIT) an expansion-stage alternative construction and real estate development company, today announced an initiative to protect its long-term shareholders by offering Convertible Preferred Shares.

“Over the past few weeks, we have experienced a lot of progression in our business model, due in part to our Stimulus Package and the issuance of Anti-Dilutive, Convertible Preferred Shares,” stated Patrick J. Johnson, CEO of Cherubim Interests, Inc.

“Some weeks ago, the company amended its Articles of Incorporation and Corporate Bylaws to create a series of Convertible Preferred Shares in order to protect its shareholders who have securities that are ‘underwater’ after purchase in the open market,” added Johnson.

“We devised a playbook to handle exactly this type of scenario and it has served its purpose as a road-map for charting a course through these transitionary stages,” continued Johnson.

“This route has enabled the company to remove any future compounding derivative liabilities on the balance sheet,” said Johnson. “We are now pleased to announce that the company has retired the majority of this ‘toxic’ type of debt.”

Shareholders who have been holding a minimum of 100,000 shares of Common Stock dating back to May 1, 2015, and were affected by this dilution, are asked to contact the Company at golong@cherubiminterests.com. Representatives will then arrange the verification and the issuance of convertible preferred shares.

“Obviously the Company seeks to protect the integrity of the investments made by our stockholders,” stated Johnson, “as we realize that this process has impacted some of them greatly and this is a way for the company to shore up these investors.”

The company to date has converted over a half-million dollars of its principal affiliate debt and will be filed in form 8k in the coming days. The company also expects to remove additional Principle Affiliate Debt in the very near future.

Concerning the previously announced convertible preferred stock dividend, Johnson said the company is currently waiting on approval from FINRA and anticipates to have it finalized shortly.

Learn more about Cherubim Interests by visiting www.cherubiminterests.com

Let us hear your thoughts: Cherubim Interests, Inc. Message Board

Oakridge Global Energy Solutions (OTC: OGES) has set its sights on the $10 billion unmanned aerial vehicle (UAV) market with its lithium ion batteries, and for good reason. According to a recent report, UAVs or drones will continue to be ‘the most dynamic growth sector of the world aerospace industry’ in the coming decade. Another study estimates the global market for UAVs will grow at an annual compounded rate of 8.12% over the next five years to reach $15 billion in 2020. A lot of this action will be in the U.S. which, at present, accounts for about 65% of the global drone market, and it’s heating up. For example, Facebook (NASDAQ: FB) has developed a drone, called Aquila, which it will use to provide internet access to remote locations.

Oakridge is now poised to deliver cells and battery packs for drones in the recreational remote control market, the film industry, agriculture, law enforcement and the military. The company has branded this battery line the Patriot Series. But it’s not just the skies that have caught Oakridge’s attention. The company has also developed pressure tolerant cells for Unmanned Underwater Vehicles (UUV). These robots are flooded machines in which the battery itself is exposed to deep sea pressures of up to 10,000 pounds per square inch (sea level air pressure is 14.7 psi).

Oakridge’s cells have passed this rigorous abuse testing by the U.S. Navy’s testing laboratory, Caderock, and have been qualified for deployment on the UUVs. Oakridge has its feet firmly on the ground, too. In January 2015, it launched a new range of large format prismatic batteries for the worldwide golf car and local area electric vehicle market. This battery line has been branded the Pro Series. The launch took place at the annual PGA golf show in Orlando, Florida, believed to be the largest golf show in the world. (Prismatic battery cells are rectangular and, while not as efficient as the familiar cylindrical cells, utilise space much more efficiently because of their shape)

Florida is betting on Oakridge. The company has received a $33 million incentive package from the state of Florida, the local county (Brevard County) and the city of Palm Bay. Recently Governor Rick Scott was on hand to open Oakridge’s new corporate headquarters in Palm Bay. The company’s 50,492 square feet manufacturing facility is at Sarno Road in Melbourne, FL. It has the ability to manufacture six megawatt hours of products annually.

CEO Steve Barber expects Oakridge to be producing its first significant revenues during the first quarter of 2016, and to be cash flow positive by the end of that quarter. After a tour of the company’s manufacturing facilities, Governor Scott told reporters “Oakridge Global Energy Solutions could have moved their headquarters anywhere in the world, and I am proud to announce that they chose to remain in Florida and create 1,000 new jobs.” With such an exciting future, Oakridge Global Energy Solutions is certainly no drone.

For more information, visit www.oakg.net

Let us hear your thoughts: Oakridge Global Energy Solutions, Inc. Message Board

Sufferers of chronic headaches and/or migraines know the difficulties of a grocery store trip. Certain ingredients, chemicals, and additives can trigger these painful attacks, making the task of food shopping tedious. Fortunately, ContentChecked Holdings, Inc. (OTC: CNCK) has developed an app that lets users know if the foods they’re putting into their carts contain risky ingredients. After scanning an item’s barcode, the MigraineChecked app will let the user know if any ingredients are migraine triggers. This app offers users a simple approach to preventing migraine headaches while making healthy choices.

According to the Migraine Research Foundation, over 10% of the world’s population suffers from migraines. More than 90% of these people cannot function properly during an attack, which results in school or work absences. In the United States alone, 36 million people suffer from the syndrome with 14 million people experiencing painful episodes each day. These numbers are hard to ignore, making the MigraineChecked app a valuable tool for prevention.

The whole premise of MigraineChecked is to alert the user of foods containing migraine-causing ingredients. Some of these ingredients are hard to identify; that’s when the app steps in. Processed foods with monosodium glutamate (MSG), artificial sweeteners, nitrates, nitrites, and flavor enhancers are known to cause the syndrome. Even chocolate, alcohol, caffeine, peanuts, and cheeses containing tyramine are common triggers. The app will immediately alert the user if any of these pesky potential elements are present in a food item.

ContentChecked aims to arm consumers with nutritional data that can help them make informed grocery choices for their specific dietary needs while promoting a healthy lifestyle. The app and website also offer delicious recipes with customizable dietary restrictions to suit everyone’s tastes. These recipes include appetizers, desserts, beverages, and entrees. The company will continue developing more apps, such as VeganChecked, in order to reach a wider audience.

For more information, visit the company’s website at www.contentchecked.com

Lingo Media Corp. (OTC: LMDCF) (TSX-V: LM), an EdTech company, began its vision of “helping the world learn English” about 15 years ago with its Lingo Learning business unit. The company was one of the early pioneers in the Chinese educational market, and has since brought over 520 million learning products to students ranging from kindergarten all the way up to young professionals. Lingo Media, along with its co-publishing partners, People’s Education Press and PEP Audio Visual Press, dominates 60% of China’s primary school market. The company’s other business unit, ELL Technologies, has also gained speed with its advanced technological solutions designed to give students even more English language success.

Lingo Media strives to make learning English as effective as possible. That’s why the company blends best practice theories with the latest technology. ELL Technologies provides the only virtual conversation tool in its Speaking Lab where students can have a conversation with an avatar in English before experimenting with an actual person. Immersion is a great way for students to learn any language.

Lingo Learning, on the other hand, offers textbook and other print solutions to students that include content developed by educational experts. These include 350 program titles for preschoolers to postsecondary students.

With these tools, students can learn at their own pace with access to guidance and feedback on their progress.

The company also delivers a customizable business platform to its customers. It works individually with each partner to guarantee an enriching user experience. Lingo Media understands the importance of establishing flexible solutions to meet cultural and regional needs. Though it currently has a large presence in China, the company intends to expand to Latin America and other Asian markets in the near future.

Lingo Media aims to bring “excellent, affordable and effective English language learning solutions that will help make the world a little smaller.” Since its start, the company has helped more than 20 million students in over 10 countries improve their English and shows no sign of slowing down.

For more information on the company, visit www.lingomedia.com

Let us hear your thoughts: Lingo Media Corp. Message Board